Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325101 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03325101: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03325101 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03325101, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after cryosurgery in combination with pembrolizumab may work better in treating patients with melanoma.
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Cryosurgery
- PROCEDURE Pheresis
- BIOLOGICAL Therapeutic Autologous Dendritic Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2020-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03325101
The ClinicalTrials.gov registry entry for NCT03325101 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03325101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03325101 about?
NCT03325101 is a clinical study titled "Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma". This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body buil...
What is the current status of trial NCT03325101?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-11-15. Estimated completion is 2020-06-14.
What interventions are being tested in trial NCT03325101?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cryosurgery (PROCEDURE), Pheresis (PROCEDURE), Therapeutic Autologous Dendritic Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03325101?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.